What Larin Fe 1 / 20 Treats: Main Uses and Benefits

Quick Facts

• A form of hormonal contraception intended to prevent pregnancy.
• May be utilized to manage moderate acne in certain women seeking an oral contraceptive method.

Larin Fe 1/20 is a prescription medication indicated for women to prevent pregnancy (contraception). It is a combination oral contraceptive that contains two hormonal components: norethindrone acetate and ethinyl estradiol. The primary action of this medication contributes to the reduction of the probability of conception.

In addition to its role in family planning, Larin Fe 1/20 may be prescribed for the management of moderate acne vulgaris in women who have reached menarche and are also seeking to use an oral contraceptive for birth control. This use is based on the established clinical profile of the drug's components.

It is important to note that this product does not offer protection against HIV infection (AIDS) or other sexually transmitted infections.

Regulatory References

1. FDA Professional Labeling Guidance

Eligibility: Who Can and Cannot Use Larin Fe 1/20

Larin Fe 1/20 is indicated only for postmenarchal women of reproductive potential for pregnancy prevention. Its use is strictly defined by numerous absolute contraindications documented in official regulatory labeling.

---

Absolute Contraindications

This medication must not be used in women over 35 years of age who smoke due to the significantly increased risk of serious cardiovascular events. It is also contraindicated in patients with a history of deep vein thrombosis, pulmonary embolism, or other thromboembolic disorders. Patients with coronary artery disease, uncontrolled hypertension, diabetes mellitus with vascular disease, or certain types of migraines (especially with aura) are ineligible for use.

Organ Function and Comorbidity Restrictions

Use is prohibited for patients with a current or past history of breast cancer or other estrogen-dependent neoplasia, liver tumors, or active liver disease. The medicine is contraindicated during pregnancy and is not recommended for women who are breastfeeding. Additionally, the medicine must be discontinued at least four weeks before and two weeks after any major surgery or prolonged immobilization.

Interactions with other medicines and products

This section outlines officially documented interaction patterns for Larin Fe 1/20 (Ethinyl Estradiol, Norethindrone Acetate, and Ferrous Fumarate) based on government regulatory information.

Contraindicated Combinations

Co-administration with specific drug regimens for Hepatitis C containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, is prohibited due to the risk of significant liver enzyme (ALT) elevations.

Pharmacokinetic and Exposure Alterations

Certain medicinal products can alter the plasma concentrations of the contraceptive hormones. These interactions generally fall into two categories:

• Reduced Contraceptive Exposure: Drugs that increase hormone metabolism, such as Rifampin, some anticonvulsants (e.g., phenytoin, carbamazepine), and the herbal product St. John's Wort, can significantly decrease the levels of Ethinyl Estradiol and Norethindrone.
• Altered Co-drug Levels: The contraceptive hormones may increase the plasma concentration of certain co-administered drugs like Cyclosporine and Prednisolone, or decrease the levels of others, such as Acetaminophen and Morphine.

Non-Hormonal Component Interaction

Ferrous Fumarate (iron) in the inactive tablets can interact with certain substances, requiring time separation. Iron absorption may be reduced if taken concurrently with medications like Thyroid Medications or Quinolone Antibiotics, or with certain dietary items such as coffee, tea, or dairy products.

Population-Specific Notes

In women with impaired liver function, the hormonal components may be poorly metabolized, potentially intensifying the interaction profile. Higher Ethinyl Estradiol concentrations have also been documented in women with chronic renal failure.

How Larin Fe 1 / 20 Works

The mechanism of action for Larin Fe 1 / 20 involves the modulation of key hormonal signaling pathways through the synthetic estrogen, ethinyl estradiol, and the progestin, norethindrone, resulting in defined physiological effects. These compounds engage distinct biological domains to regulate the reproductive axis.

---

Inhibition of Gonadotropin Secretion

This central domain centers on the hypothalamic-pituitary-ovarian (HPO) axis. The synthetic hormones act via negative feedback on the hypothalamus and anterior pituitary gland, thereby suppressing the pulsatile release of gonadotropin-releasing hormone (GnRH) and, consequently, the pituitary hormones, luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This mechanistic cascade results in the suppression of ovarian follicle maturation and the abatement of the mid-cycle LH surge; the reduction of LH and FSH concentrations modulates the physiological sequence leading to follicular rupture.

---

Alteration of Endometrial and Cervical Biology

This domain encompasses the local effects of the synthetic hormones on target tissues within the reproductive tract. The continuous administration of progestin induces structural changes in the endometrium, causing it to become atrophic and less receptive. Simultaneously, the progestin thickens the cervical mucus, resulting in a highly viscous and altered cervical environment that limits sperm motility. These effects modulate the processes of endometrial receptivity and gamete transit.

Official Administration Guidelines for Larin Fe 1 / 20

Larin Fe 1/20 is used according to a standardized oral, fixed-dose, 28-day cyclic regimen. The administration pattern dictates that one tablet daily is taken without interruption, ensuring a consistent dose of 1 mg norethindrone acetate and 20 mcg ethinyl estradiol during the active phase of the cycle.

Procedural Use Requirements

Parameter	Official Instruction/Regimen
Route of Administration	Oral
Dosing Schedule	One tablet taken once daily
Cycle Structure	21 active hormone tablets followed by 7 inactive (ferrous fumarate) tablets
Timing Constraint	Must be taken at the same time each day
Age Group Use	Approved for use in postpubertal adolescents

This continuous cyclic use requires tablets to be taken sequentially in the order presented in the blister pack to maintain the intended hormone delivery schedule. A new 28-day pack is started immediately after the last tablet of the previous pack is completed. Specific procedural steps are provided for the handling of missed active tablets, which details the required actions and potential need for a temporary backup non-hormonal administration method to ensure regimen continuity.

Larin Fe 1 / 20: Recent Clinical Evidence

Evidence for Use in Pregnancy Prevention (Contraception)

Research exploring the use of combination oral contraceptives, including those with Norethindrone Acetate and Ethinyl Estradiol, involves pivotal short-term randomized controlled trials (RCTs) and large-scale observational studies. This research examined the components in relation to pregnancy rates in women of reproductive potential. The core outcomes measured in these studies are related to systemic balance, quantified using a specific measure called the Pearl Index to track observed rates of pregnancy. Findings derived from regulatory trials describe patterns related to the Pearl Index rate as measured in the study populations. Evidence describing multi-year functioning and outcomes in certain non-healthy subgroups may be limited, often relying on broader observational data related to combination oral contraceptives as a class.

---

Evidence for Use in the Management of Moderate Acne

This formulation was evaluated in research contexts involving moderate acne vulgaris. Studies explored the use of this combination in women with moderate acne who were also seeking contraception, involving randomized, double-blind, placebo-controlled trials. These studies examined patient-reported outcomes and objective outcomes related to inflammatory states. Researchers monitored changes in skin scores, such as total acne lesion counts, and utilized the Investigator's Global Assessment (IGA). Trials reported measurements of the IGA score and reductions in lesion counts over observation periods typically lasting around six months. Data for the durability of reported changes beyond this typical trial period may be insufficient.

---

What is Still Uncertain About Larin Fe 1 / 20

The primary efficacy trials for pregnancy prevention generally cover a time frame of 6 to 13 menstrual cycles, and long-term evidence is often sought from extended epidemiological studies of combination oral contraceptives in general. Research into long-term outcomes and the monitoring of certain rare conditions are not fully established. Comparative evidence is also lacking in some areas, such as the direct clinical assessment of its outcomes against all alternative low-dose contraceptive formulations. Research provides context but not individual predictions, describing group patterns, not personal outcomes.

Key Studies & References DailyMed Labeling: Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate Tablets (Larin Fe 1/20)

Common questions about Larin Fe 1 / 20 (FAQ)

---

Q: How does the 'Fe' part of Larin Fe 1 / 20 relate to the medicine's purpose?

The 'Fe' in the name stands for ferrous fumarate, which is a form of supplemental iron. This component is found only in the seven non-hormonal (inactive) pills included in the 28-day pack. According to official labeling, these pills are documented as being non-hormonal and are not responsible for the contraceptive action.

---

Q: Are the active ingredients in Larin Fe 1 / 20 similar to those in Junel Fe 1/20?

Yes, Larin Fe 1/20 and Junel Fe 1/20 are combination oral contraceptives formulated with the same active hormonal components: norethindrone acetate and ethinyl estradiol. The inactive tablets in both products also contain ferrous fumarate.

---

Q: What's the difference between Larin Fe 1 / 20 and a pill with a higher hormone dose?

Larin Fe 1/20 is specifically classified as a low-dose combination oral contraceptive. This classification is based on the low amount of ethinyl estradiol it contains. Other available formulations may contain higher quantities of ethinyl estradiol.

---

Q: How quickly is Larin Fe 1 / 20 generally expected to start working for its main purpose?

Official patient instructions indicate that this medication is not considered effective for contraception until after the first seven consecutive days of active tablet administration. For this reason, a back-up method is often mentioned in official documentation for the initial period.

---

Q: Does Larin Fe 1 / 20 affect mood or cause emotional changes?

Yes, official labeling notes that mood changes and mood swings have been reported as common adverse reactions (occurring in 2% or more of users) in clinical studies. Official information includes a precaution to observe users with a history of depression.

---

Q: What is the purpose of the inactive pills (sometimes called 'placebo' pills)?

The purpose of the inactive tablets is to help facilitate the easy and consistent administration of the daily 28-day regimen. These pills are non-hormonal, but they do contain ferrous fumarate (iron). Taking one pill daily, including the inactive ones, helps a person maintain the habit without interruption.

---

Q: Can taking Larin Fe 1 / 20 at a slightly different time each day affect its function?

Regulatory documents emphasize that the pill must be taken at the same time every day for maximum contraceptive effectiveness. Regulatory documents note that tablets should not be taken at intervals that significantly exceed 24 hours.

---

Q: What is the most common reason Larin Fe 1 / 20 is prescribed besides pregnancy prevention?

The primary indication for this medication is pregnancy prevention. However, research supporting the drug’s use in the management of moderate acne vulgaris in women seeking oral contraception is also included in official documentation.

---

Q: Is Larin Fe 1 / 20 effective for regulating an irregular cycle?

The drug is primarily indicated for pregnancy prevention. While it is a combination hormonal contraceptive that results in a predictable withdrawal bleed, official labeling discusses the possibility of evaluating bleeding irregularities that may occur during its use.

---

Q: Is it normal to have a very light period, or no period, while on Larin Fe 1 / 20?

Official product information states that amenorrhea (absence of bleeding) and irregular bleeding are recognized possibilities when taking this medication. Official product information describes that a healthcare provider may need to evaluate any unexpected bleeding patterns.

---

Q: What are the components of the 'Fe' pills in the pack?

The seven inactive pills in the pack contain ferrous fumarate (iron). Like any tablet, they also contain standard inactive ingredients (binders, fillers) necessary to form the pill.

---

Q: What is the general expectation for fertility after stopping Larin Fe 1 / 20?

According to general information on combination oral contraceptives, fertility usually returns rapidly after stopping the medication. A delay in the first spontaneous ovulation following discontinuation is uncommon.

---

Q: What are the official recommendations if vomiting occurs shortly after taking Larin Fe 1 / 20?

Official product information states that in cases of severe vomiting or diarrhea shortly after taking an active tablet, the instructions for handling missed tablets may be applicable. This guidance is necessary because the absorption of the tablet may be incomplete.

---

Q: Does Larin Fe 1 / 20 affect routine blood tests or lab results?

Yes, official documentation states that the use of this medication may affect the results of certain common laboratory tests. These include tests related to thyroid function, lipid metabolism (cholesterol/triglycerides), and blood clotting (coagulation) factors.

---

Q: Why do some people stop taking Larin Fe 1 / 20?

The most common reasons for discontinuation in clinical trials were related to adverse reactions. These often included headache, nausea, menstrual cramps, and bleeding irregularities. Other documented reasons include the development of a medical condition that is a regulatory contraindication for use.

Official Storage and Disposal Requirements

Larin Fe 1 / 20 must be stored under specific conditions to maintain the stability of its hormonal components, as defined by regulatory standards.

Requirement Type	Official Labeled Condition
Temperature	Store at 20 C to 25 C (68 F to 77 F).
Protection	Protect from light; storage adheres to USP Controlled Room Temperature standards.
Child Safety	Keep this product out of reach of children.
Disposal	Dispose of unused or expired product according to local regulations.

Storage must strictly remain within the Controlled Room Temperature range. The medication must also be shielded from light, and it is mandatory to keep the blister packaging out of the reach of children. This requirement is explicitly tied to the risk of accidental poisoning from the ferrous fumarate (iron) component. Final disposal of unused tablets must follow the specific pharmaceutical waste protocols established by local authorities.